Positive Outlook for aTyr Pharma: Buy Rating Reaffirmed Amid Promising EFZO-FIT Trial Prospects

Analyst Faisal Khurshid from Leerink Partners reiterated a Buy rating on aTyr Pharma (ATYR – Research Report) and keeping the price target at $16.00.

Faisal Khurshid has given his Buy rating due to a combination of factors including the promising outlook for aTyr Pharma’s upcoming Phase 3 EFZO-FIT trial results for efzofitimod in pulmonary sarcoidosis, expected in the third quarter of 2025. The trial is anticipated to be a significant value inflection point for the company, supported by encouraging data from previous Phase 1b/2a studies, positive feedback from key opinion leaders, and a comprehensive analysis of the underlying science.
Additionally, the company’s management provided insights into the baseline characteristics of the EFZO-FIT trial, which will be presented at an upcoming conference. The trial’s design, including adjustments to the statistical analysis plan following discussions with the FDA, further strengthens confidence in the potential outcomes. These elements collectively contribute to the positive outlook and the reiterated Outperform rating for aTyr Pharma.

Khurshid covers the Healthcare sector, focusing on stocks such as Pliant Therapeutics, aTyr Pharma, and Ironwood Pharma. According to TipRanks, Khurshid has an average return of 27.5% and a 46.48% success rate on recommended stocks.

In another report released on May 8, Piper Sandler also maintained a Buy rating on the stock with a $20.00 price target.